Obesity‑care guidelines roundup
A new review in AJMC shows that obesity treatment is now firmly treated as mainstream clinical care, not a niche specialty — guidelines and best practices are evolving quickly as treatments and delivery models change. (ajmc.com) That matters because it frames weight management as a standard part of primary care and signals why new pharmacological and behavioral options are scaling. (ajmc.com)
Obesity care used to sit off to the side like a specialty clinic problem. The newer guidance treats it more like high blood pressure or diabetes: a chronic disease that primary care is expected to screen for, diagnose, and manage over time. (ajmc.com) That shift starts with a basic idea: body mass index, or BMI, is only a first pass, like checking a smoke alarm instead of inspecting the whole house. The American Association of Clinical Endocrinology says clinicians should also look for complications such as type 2 diabetes, fatty liver disease, sleep apnea, and cardiovascular disease before choosing treatment. (ajmc.com) (aace.com) Behavior change is still the foundation, but guidelines no longer treat “eat less and move more” as a complete plan by itself. The U.S. Preventive Services Task Force recommends offering or referring adults with obesity to intensive, multicomponent behavioral interventions, which means structured programs rather than a quick lecture at the end of a visit. (uspreventiveservicestaskforce.org) Medicare has covered intensive behavioral therapy for obesity for years, which shows how far this has moved into routine care. The federal coverage decision applies to beneficiaries with a body mass index of 30 kilograms per square meter or higher and includes counseling focused on diet and exercise in primary care settings. (cms.gov) (medicare.gov) The big change since many older guidelines were written is medication. The American Gastroenterological Association said in 2022 that anti-obesity drugs should be added to lifestyle intervention for adults with obesity who have had insufficient response to lifestyle intervention alone. (gastrojournal.org) By 2024 and 2025, major groups were pushing even harder toward earlier use. The American Heart Association said obesity science was not making it into everyday practice fast enough, and the European Association for the Study of Obesity went further by naming semaglutide or tirzepatide as first-line drug treatment for many patients with obesity and related complications. (acc.org) (nature.com) That is a sharp break from the old step-therapy mindset where patients were often told to fail lifestyle treatment over and over before getting anything else. Newer guidance treats obesity as a relapsing disease, which means long-term treatment can be appropriate in the same way long-term blood pressure medicine is appropriate. (who.int) (heart.org) The language is changing too. European guidance published in Nature Medicine in 2024 framed obesity as an adiposity-based chronic disease, which moves the focus away from weight alone and toward excess body fat that is already damaging organs or raising risk. (nature.com) Global health agencies are now writing drug guidance that barely existed a few years ago. In December 2025, the World Health Organization issued its first guideline on glucagon-like peptide-1 therapies for adults with obesity and described the condition as chronic and relapsing while also warning health systems to plan for workforce, supply, and cost pressures. (who.int) (paho.org) The practical result is that obesity care is being rebuilt around tiers: structured counseling first, medication when indicated, surgery for selected patients, and follow-up that assumes relapse can happen. That is why reviews like the one in The American Journal of Managed Care read less like a niche update and more like a map of how standard medical practice is being rewritten in real time. (ajmc.com 1) (ajmc.com 2)
